Tazemetostat Hydrobromide Patent Expiration
Tazemetostat Hydrobromide is used for treating certain types of sarcoma and relapsed or refractory follicular lymphoma with EZH2 mutations. It was first introduced by Epizyme Inc
Tazemetostat Hydrobromide Patents
Given below is the list of patents protecting Tazemetostat Hydrobromide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tazverik | US12168014 | Method for treating cancer | May 03, 2038 | Epizyme Inc |
| Tazverik | US10786511 | Method for treating cancer | Dec 19, 2035 | Epizyme Inc |
| Tazverik | US10369155 | Method for treating cancer | Oct 16, 2035 | Epizyme Inc |
| Tazverik | US9889138 | Method for treating cancer | Oct 16, 2035 | Epizyme Inc |
| Tazverik | US9688665 | Methods of treating cancer | Aug 22, 2034 | Epizyme Inc |
| Tazverik | US12162865 | Methods of treating cancer | May 21, 2034 | Epizyme Inc |
| Tazverik | US8410088 | Aryl- or heteroaryl-substituted benzene compounds | Jan 23, 2034 | Epizyme Inc |
| Tazverik | US10245269 | Salt form of a human histone methyltransferase EZH2 inhibitor | Apr 11, 2033 | Epizyme Inc |
| Tazverik | US10821113 | Salt form of a human histone methyltransferase EZH2 inhibitor | Apr 11, 2033 | Epizyme Inc |
| Tazverik | US11491163 | Salt form of a human histone methyltransferase EZH2 inhibitor | Apr 11, 2033 | Epizyme Inc |
| Tazverik | US9394283 | Salt form of a human histone methyltransferase EZH2 inhibitor | Apr 11, 2033 | Epizyme Inc |
| Tazverik | US9872862 | Salt form of a human histone methyltransferase EZH2 inhibitor | Apr 11, 2033 | Epizyme Inc |
| Tazverik | US11052093 | Aryl-or heteroaryl-substituted benzene compounds | Apr 13, 2032 | Epizyme Inc |
| Tazverik | US9522152 | Aryl- or heteroaryl-substituted benzene compounds | Apr 13, 2032 | Epizyme Inc |
| Tazverik | US10155002 | Aryl- or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US10420775 | Aryl-or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US12161645 | Aryl-or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US12168015 | Aryl-or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US12168016 | Aryl-OR heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US8691507 | Inhibitors of human EZH2 and methods of use thereof | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US8765732 | Aryl- or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US8895245 | Inhibitors of human EZH2 and methods of use thereof | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9090562 | Aryl- or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9175331 | Inhibitors of human EZH2, and methods of use thereof | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9333217 | Inhibitors of human EZH2, and methods of use thereof | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9334527 | Inhibitors of human EZH2, and methods of use thereof | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9549931 | Aryl- or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9855275 | Aryl-or heteroaryl-substituted benzene compounds | Sep 12, 2031 | Epizyme Inc |
| Tazverik | US9949999 | Inhibitors of human EZH2, and methods of use thereof | Sep 12, 2031 | Epizyme Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tazemetostat Hydrobromide's patents.
Latest Legal Activities on Tazemetostat Hydrobromide's Patents
Given below is the list recent legal activities going on the following patents of Tazemetostat Hydrobromide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549931 |
| Patent eCofC Notification | 11 Jun, 2024 | US9394283 |
| Recordation of Patent eCertificate of Correction | 11 Jun, 2024 | US9394283 |
| Mail Patent eCofC Notification | 11 Jun, 2024 | US9394283 |
| Email Notification Critical | 11 Jun, 2024 | US9394283 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jun, 2024 | US9522152 |
| Email Notification Critical | 17 Apr, 2024 | US9889138 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10821113 |
| Email Notification Critical | 16 Apr, 2024 | US9889138 |
| Mail Patent eCofC Notification | 16 Apr, 2024 | US9889138 |
Tazemetostat Hydrobromide's Family Patents
